|
|
|
|
Hypersensitivity Reactions To The Quadrivalent HPV Vaccine Are Rare, British Medical Journal
Hypersensitivity reactions to the quadrivalent HPV vaccine (4vHPV, Gardasil) are uncommon and most schoolgirls can tolerate subsequent doses, finds the first evaluation of the quadrivalent HPV vaccine published on today.In Australia...
|
|
|
Hypersensitivity Reactions to the Quadrivalent HPV Vaccine Are Rare
Newswise Hypersensitivity reactions to the quadrivalent HPV vaccine (4vHPV, Gardasil) are uncommon and most schoolgirls can tolerate subsequent doses, finds the first evaluation of the quadrivalent HPV vaccine published on bmj.com...
|
|
|
True Hypersensitivity to HPV Vaccine Is Uncommon, Say Australian Researchers
_ True Hypersensitivity to HPV Vaccine Is Uncommon, Say Australian Researchers.
|
|
|
True Hypersensitivity to HPV Vaccine Is Uncommon, Say Australian Researchers
_ True Hypersensitivity to HPV Vaccine Is Uncommon, Say Australian Researchers.
|
|
|
Clinical Features of Hypersensitivity Reactions to Oxaliplatin: A 10-Year Experience
aMedical Oncology Unit and bGeneral Surgery Department, Laiko General Hospital, Athens University School of Medicine, Athens, and cMedical Oncology Unit, University General Hospital of Heraklion, Heraklion, Greece Key Words Oxaliplatin ...
|
|
|
Research and Markets: Immunotoxicology Strategies for Pharmaceutical Safety Assessment Revealed
Research and Markets (http://www.researchandmarkets.com/research/f6d7c3/immunotoxicology_s) has announced the addition of John Wiley and Sons Ltd's new report 'Immunotoxicology Strategies for Pharmaceutical Safety Assessment' to their...
|
|
|
Research and Markets: Immunotoxicology Strategies for Pharmaceutical Safety Assessment Revealed
(M2 PRESSWIRE via COMTEX) -- JW/A | Quote | Chart | News | PowerRating -- Research and Markets (http://www.researchandmarkets.com/research/f7ca6e/immunotoxicology_s) has announced the addition of John Wiley and Sons Ltd's new report ...
|
|
|
Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately
WOODCLIFF LAKE, N.J., Nov.19 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that it has entered into a supply and distribution agreement with AstraZeneca in the U.S. to market budesonide inhalation...
|
|
|
Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately
/PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc.today announced that it has entered into a supply and distribution agreement with AstraZeneca in the U.S. to market budesonide inhalation suspension, which is a generic form of...
|
|
|
Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately
WOODCLIFF LAKE, N.J., Nov.19 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has entered into a supply and distribution agreement with AstraZeneca in the U.S. to market budesonide...
|
|
|
Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately
WOODCLIFF LAKE, N.J., Nov.19 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has entered into a supply and distribution agreement with AstraZeneca in the U.S. to market budesonide...
|
|
|
Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately
WOODCLIFF LAKE, N.J., Nov.19 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has entered into a supply and distribution agreement with AstraZeneca in the U.S. to market budesonide...
|
|
|
Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately
WOODCLIFF LAKE, N.J., Nov.19 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has entered into a supply and distribution agreement with AstraZeneca in the U.S. to market budesonide...
|
|
|
Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately
WOODCLIFF LAKE, N.J., Nov.19 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has entered into a supply and distribution agreement with AstraZeneca in the U.S. to market budesonide...
|
|
|
Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately
WOODCLIFF LAKE, N.J., Nov.19 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX - News) today announced that it has entered into a supply and distribution agreement with AstraZeneca in the U.S. to market...
|
|
|
Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately
/PRNewswire-FirstCall via COMTEX/ -- Par Pharmaceutical Companies, Inc.(PRX: PRX News, chart, profile, more Last: Delayed quote data Add to portfolio Analyst Create alert Insider Discuss Financials Sponsored by: , , ) today announced that...
|
|
|
Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately
WOODCLIFF LAKE, N.J., Nov.19 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that it has entered into a supply and distribution agreement with AstraZeneca in the U.S. to market budesonide inhalation...
|
|
|
Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately
WOODCLIFF LAKE, N.J., Nov.19 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has entered into a supply and distribution agreement with AstraZeneca in the U.S. to market budesonide...
|
|
|
GARDASIL(R), Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males
GARDASIL[Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], the cervical cancer vaccine from Merck & Co., Inc., prevented 90 percent of external genital lesions caused by human papillomavirus (HPV)...
|
|
|
Hypersensitivity to cyclooxygenase inhibitory drugs in children: a study of 164 cases
Hassani A et al.- Cross-reactivity was frequent, suggesting that most reactions resulted from a non allergic hypersensitivity linked to the pharmacological properties of the drugs. However, in a few children, the reactions may result...
|
|
|
Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in
WASHINGTON, Oct.28 /PRNewswire-AsiaNet/ -- - Data presented at the joint annual meeting of ICAAC and IDSA - Results suggest candidate vaccine may be as effective as Prevnar for the seven shared serotypes, and provide expanded coverage for...
|
|
|
Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in
- Data presented at the joint annual meeting of ICAAC and IDSA - Results suggest candidate vaccine may be as effective as Prevnar for the seven shared serotypes, and provide expanded coverage for six additional serotypes - Wyeth on track to...
|
|
|
Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in
/PRNewswire-FirstCall via COMTEX/ -- WYE | Quote | Chart | News | PowerRating -- - Data presented at the joint annual meeting of ICAAC and IDSA - Results suggest candidate vaccine may be as effective as Prevnar for the seven shared serotypes...
|
|
|
Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in
- Data presented at the joint annual meeting of ICAAC and IDSA - Results suggest candidate vaccine may be as effective as Prevnar for the seven shared serotypes, and provide expanded coverage for six additional serotypes - Wyeth on track to...
|
|
|
Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in
- Data presented at the joint annual meeting of ICAAC and IDSA - Results suggest candidate vaccine may be as effective as Prevnar for the seven shared serotypes, and provide expanded coverage for six additional serotypes - Wyeth on track to...
|
